QR Kod

A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC

Introduction: Evidence supports the addition of immunotherapy to definitive chemoradiation for unresectable stage IIIA NSCLC. Adding pembrolizumab to neoadjuvant chemoradiation in patients with resectable stage IIIA NSCLC requires study for safety and feasibility. Methods: Patients with resectable s...

Ful tanımlama

Kaydedildi:
Asıl Yazarlar: Christopher A. Lemmon, MD, Gregory M.M. Videtic, MDCM, Sudish Murthy, MD, PhD, Kevin L. Stephans, MD, Marc Shapiro, MD, Usman Ahmad, MD, Daniel Raymond, MD, Vamsidhar Velcheti, MD, Alejandro Bribriesco, MD, Xuefei Jia, MS, James Stevenson, MD, Nathan A. Pennell, MD, PhD
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Elsevier 2022-07-01
Seri Bilgileri:JTO Clinical and Research Reports
Konular:
Neoadjuvant
Chemoradiation
Immunotherapy
NSCLC
Online Erişim:http://www.sciencedirect.com/science/article/pii/S2666364322000832
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller